Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM4GWL7)

Drug Name	Gefapixant DM4GWL7
Synonyms	UNII-6K6L7E3F1L; 6K6L7E3F1L; MK-7264; 1015787-98-0; Gefapixant [USAN]; GTPL9540; SCHEMBL1493905; CHEMBL3716057; HLWURFKMDLAKOD-UHFFFAOYSA-N; ZINC116342482; J3.556.891C; 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide; 2-Methoxy-4-isopropyl-5-(2,4-diamino-5-pyrimidinyloxy)benzenesulfonamide; 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide; 5-((2,4-Diaminopyrimidin-5-yl)oxy)-2-methoxy-4-(propan-2-yl)benzenesulfonamid
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Cough	DIS51FA4	MD12	Phase 3	[1]
------------------------------------------------------------------------------------

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Overactive bladder	DISQR5TD	GC50.0	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2	ClinicalTrials.gov (NCT02477709) A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).